Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxigene has published positive results of a preclinical study evaluating the combination of vascular disrupting agents (VDAs) with an antiangiogenic drug to enhance suppression of tumor growth in mice.
Subscribe to our email newsletter
Using an antiangiogenic drug which cut off blood vessels, 24 hours prior to administration of Oxigene’s VDAs resulted in markedly enhanced anti-tumor activity in the study.
“We believe that our results now provide a mechanism to explain the basis for the superior potential efficacy of such a combination involving an antiangiogenic drug with a vascular disrupting agent.” commented Dr Kerbel Dr. Kerbel, Professor in University of Toronto’s Department of Medical Biophysics
“We believe the findings from this study are of enormous importance, and will drive the intelligent development of our VDAs going forward,” said Richard Chin, President of Oxigene.
Antiangiogenesis therapy is the use of drugs or other substances to stop cancerous tumors from developing new blood vessels.